On January 9, 2026, the DOJ announced the formation of an Artificial Intelligence Litigation Task Force to challenge state laws regulating AI, following a directive from the President’s Executive Order. This Task Force aims to promote a national standard for AI regulation, reducing compliance costs for businesses while coordinating policy across the Executive Branch.
In 2026, organizations must learn from past successes in technology initiatives to effectively set AI governance goals and develop a “Skynet Strategy.” This involves assembling a diverse team, defining AI terminology, outlining beneficial use cases, inventorying AI systems, and establishing governance principles for responsible AI use.
As of early 2026, significant developments are underway in the UK’s financial services sector regarding the impact of artificial intelligence (AI). Key initiatives include the FCA’s Mills Review, a Treasury Committee report, and government appointments aimed at assessing AI’s long-term effects on retail financial services, market changes, consumer behavior, and regulatory adaptations.
The EMA and FDA have released joint guiding principles for the safe use of AI in drug development, aiming to harmonize regulatory practices. These principles emphasize ethical values, data governance, and flexibility across various AI applications to enhance innovation in the pharmaceutical sector.
Recent court decisions demonstrate that copyright claims against generative AI companies are being seriously considered. Courts refuse to dismiss allegations of infringement based on AI-generated outputs, emphasizing the importance of evaluating substantial similarity and potential market harm in cases involving AI replication of protected works.